ArticleScientific reports2025
Targeted anticancer effects of Juglone-ZnO nanoparticles via cell cycle arrest and caspase-mediated apoptosis in colon cancer cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Green synthesis of ZnO nanoparticles using bioactive compounds from the Amycolatopsis roodepoortensis strain EA7 and their effects in the HT-29 cell line.Scientific reports · 2026Article
- Biogenic synthesis of bioactive zinc nanoparticles from cyanobacterial Nostoc sp. MK-7 for biomedical applications.Discover nano · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Finding new drugs for adjuvant chemotherapy of colon cancer is of high priority. This study aimed to evaluate the antiproliferative properties and anticancer mechanisms of glucose (C) functionalized and juglone-conjugated zinc oxide (ZnO) nanoparticles (NPs) [(ZnO@C-Juglone NPs)] on a colon cancer cell line (SW480). Physicochemical properties of the NPs were characterized by FT-IR, XRD, TEM, SEM-EDS, TGA, zeta potential and DLS analyses. MTT assay was used to explore the antiproliferative potential of the NPs. Cell cycle analysis and frequency of cell apoptosis and necrosis were determined by flow cytometry. Nuclear alteration and caspase-3 activity following treatment with ZnO@C-Juglone were determined and expression of the CASP8 and CASP9 genes as well as caspase-3 activity was evaluated to explore both intrinsic and extrinsic apoptosis pathways. The FT-IR and XRD analyses confirmed the successful synthesis and structural characteristics of ZnO@C-Juglone NPs, demonstrating the presence of juglone functional groups and the crystalline nature of ZnO. The particles were spherical with a diameter range of 10-90 nm, elemental constituents of C, O, and Zn atoms, a hydrodynamic size of 275.3 nm and a zeta potential of -50.3 mV. ZnO@C-Juglone NPs exhibited dose-dependent cytotoxicity and significantly reduced the viability of cancer cells (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.